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 Introduction
 Primary liver cancer is the fifth most common cancer 
worldwide  [1] . As almost every affected individual dies, it 
is the third most common cause of cancer deaths world-
wide  [1] . Liver cirrhosis is the strongest predisposing fac-
tor for the development of a HCC  [2] . On the basis of es-
timates of the burden of hepatocellular carcinoma (HCC) 
in the US, fears arise that during the next two decades
the incidence in the US might increase to meet the inci-
dence currently observed in Japan  [3] . This rise is mainly 
attributed to the increasing spread of viral hepatitis  [4] . 
Amongst the well-defined major risk factors, alcohol 
abuse is a further leading cause for the development of 
HCC. Intake of aflatoxin via contaminated food, too, and 
different metabolic disorders are associated with an in-
creased risk for this hazard. As vaccination against hepa-
titis B  [5, 6] helped to reduce the prevalence of HCC, pre-
vention of hepatitis C, the most prominent risk factor for 
the development of HCC in developed countries, or delay 
of the disease’s progress  [7] , are hoped to further reduce 
the prevalence of HCC. Novel treatment strategies against 
HBV might help to lower this diseases burden as well  [8] . 
Patients who are afflicted with an HCC arising from an 
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 Abstract
 Background: Hepatocellular carcinoma (HCC) is the third 
most common cause of cancer deaths. Difficulties to diag-
nose HCC at early stages remain the major obstacle to cura-
tive (surgical) therapy. Therapy in advanced stages has to be 
considered palliative. In this situation, a considerable amount 
of attention should be paid to innovative treatment strate-
gies, e.g. including antiangiogenetic drugs.  Results: We re-
port on the successful treatment of a patient suffering from 
progressive HCC with a novel drug (EndoTAG  -1, formerly 
named LipoPac  ) currently investigated in phase II studies. 
This drug consists of liposomally encapsulated paclitaxel. Its 
liposomal formulation favors the drug’s adherence to the tu-
mor neovasculature, in effect starving the tumor.  Conclu-
sions: EndoTAG  -1 stopped tumor progression for 9 months 
in our patient. This, along with successes observed testing 
this drug against other indications, makes it a suitable can-
didate for future clinical trials.  Copyright © 2008 S. Karger AG, Basel
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adenoma of the liver survive significantly longer than pa-
tients suffering an HCC evolving from a cirrhotic liver  [9, 
10] .
 Noteworthy, establishment of a diagnosis is difficult 
especially in patients with cirrhosis showing only small 
nodules  [11] . In the absence of a definitive pathological 
statement, an elevated level of alpha fetoprotein together 
with nodules larger than 2 cm plus arterial hypervascu-
larization in one imaging technique can lead to the estab-
lishment of the diagnosis ‘HCC’. In 40% of all HCC, how-
ever, AFP at diagnosis is normal. Finally, the appearance 
of these nodules in two independent imaging techniques 
is considered sufficient for establishing the diagnosis as 
well  [12] . The Barcelona Clinic Liver Cancer Staging Clas-
sification of patients with HCC (BCLC) is a staging no-
menclature which is recommended by the American As-
sociation for the Study of Liver Diseases (AASLD) and the 
European Association for the Study of Liver Diseases 
(EASL)  [13] .
 Detection at early stages (BCLC stage A) allows cura-
tive treatment by transplantation, resection or percuta-
neous ablation  [2] . The optimum amongst these curative 
treatments is not established. Adjuvant chemoemboliza-
tion or chemotherapy have failed to show beneficial ef-
fects after resection  [2] , yet promising results could be 
obtained using internal radiation with iodine-131-la-
belled lipiodol and interferon  [14] , adoptive immuno-
therapy by activated lymphocytes  [15] and retinoids  [16] . 
Percutaneous treatments administering chemical sub-
stances to or altering the temperature of the neoplastic 
cells have long been considered the best option for early 
detected though unresectable (BCLC stages B or C) HCC 
 [17–20] . The median survival for patients with BCLC 
stage A, B, C or D tumors is 53, 16, 7 and 3 months, re-
spectively  [21] . In a recent phase III study  [22] , the group 
of patients receiving the orally available multikinase in-
hibitor sorafenib (Nexavar  , Bayer) achieved a median 
time to progression of 5.5 months and an overall sur-
vival duration of 10.7 months. Overall survival in the 
verum group significantly exceeded overall survival in 
the placebo group (7.9 months). Sorafenib targets the 
Raf/MEK/ERK pathway at the level of the Raf kinase and 
blocks proliferation of HCC cells. It furthermore acts an-
tiangiogenetically through the inhibition of the tyrosine 
kinases vascular endothelial growth factor receptor-2/
receptor-3 (VEGFR-2/-3) and platelet-derived growth 
factor receptor-  (PDGFR-  ). Overall survival in this 
study is not remarkably superior to the overall survival 
noted in other trials reporting about patients with BCLC 
stage B or C HCC  [23] . The combination of sorafenib or 
different multikinase inhibitors or other antiangioge-
netically active agents with cytotoxic therapy has to be 
tested against HCC in larger studies  [24] . Further op-
tions for palliative treatment are (chemo)embolization 
 [25–27] , arterial  [28] or systemic chemotherapy  [27] , in-
ternal radiation with  131 I-lipiodol  [29] , hormonal com-
pounds  [30–38] and immunotherapy  [39, 40] . A meta-
analysis  [2] of hormonal treatments with tamoxifen  [30–
36] did not show any survival benefit. A meta-analysis 
 [2] of arterial treatments ((chemo)embolization  [41–47] ) 
shows a survival benefit for well-selected patients and 
constitutes their standard treatment. Arterial emboliza-
tion has been shown to lead to a partial response in 15–55 
%  [41–47] of patients. Furthermore, has it been shown to 
delay tumor progression and vascular invasion  [43, 47] . 
Of seven randomized controlled clinical trials compar-
ing chemoembolization with conservative management, 
survival benefits for chemoembolization could be found 
in two studies  [46, 47] . Chemoembolization seems ben-
eficial for patients with a preserved liver function and 
asymptomatic nodular tumors without vascular inva-
sion or extrahepatic spread. Liver decompensation or he-
patic failure are contraindications against these options 
 [43] . Anthracyclins have recently been published to show 
efficacy against HCC  [48] . There is evidence against the 
use of paclitaxel in conventional formulations against 
HCC  [49] .
 Taken together, with the exception of the success from 
the SHARP study  [22] , no sound data basis for the recom-
mendation of one or the other palliative treatment option 
exists for patients not referable to chemoembolization. As 
is the case for many diseases in this palliative setting, 
novel treatment strategies are urgently warranted, espe-
cially taken into account the rising number of patients 
suffering from HCC. Strategies currently under observa-
tion include antiangiogenetic strategies. Thalidomide 
 [50] and bevacizumab  [51] are studied against a variety of 
neoplasms including HCC in increasing frequency. Data 
from studies of antiangiogenetic drugs against HCC are 
scarce and not convincing.
 Here, we report encouraging results obtained using an 
experimental drug as fourth line palliative chemotherapy 
for a middle-aged European male patient suffering from 
a large multilocular HCC without extrahepatic spread 
and without signs of vascular invasion (BCLC stage B). 
This drug was designed as an antiangiogenic drug and is 
referred to as EndoTAG  -1, originally named MBT-0206 
or Lipopac  . It is a save cationic liposomal formulation 
incorporating the cytostatic agent paclitaxel and has been 
developed to treat solid tumors. The drug directly targets 
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the activated endothelial cells of the tumor vascular sys-
tem  [52] . These activated endothelia exhibit properties 
differing from the normal tissue vasculature, the most 
important being a negative surface charge of the endothe-
lial cells as compared to quiescent endothelial cells in 
normal tissue. This negative charge marks a point of at-
tack and accounts for the specific binding of the posi-
tively charged liposomes to endothelial cells in the vascu-
lature of growing tumors. In the amelanotic hamster 
melanoma A-Mel-3, accumulation of cationic liposomes 
was preferred and enhanced in tumor vessels, well ob-
served in the tumors and not seen in normal tissue  [52, 
53] . EndoTAG  -1 effectively prevented melanoma growth 
and invasiveness, furthermore improved survival of the 
animals studied in a humanized SCID mouse model  [54] . 
A significant retardation of melanoma growth in Syrian 
golden hamster by EndoTAG  -1 could be observed even 
compared to free paclitaxel  [55] . The general occurrence 
of angiogenesis in all solid tumors suggests a broad ap-
plicability of this concept. The enrichment of the drug in 
tumor tissue leads to a reduction of side effects due to the 
reduced exposure of healthy tissue to cytostatic agents. 
The manufacturer of EndoTAG  -1, Medigene, has just 
reported on encouraging interim results from a phase II 
trial including 200 patients suffering inoperable, locally 
advanced or metastatic pancreatic carcinoma. In the 
group receiving the highest dose of EndoTAG  -1 next to 
gemcitabine, survival exceeded survival of the control 
group (gemcibatine only) by 30%.
 We were encouraged to use EndoTAG  -1 as fourth-
line therapy in a patient with progressive HCC.
 Case Report
 The patient was seeking medical advice in 1998 after experi-
encing pain under his right rip bow. A routine medical workup 
yielded multiple hypodensic lesions of the  right lobe of the liver 
in ultrasonography and CT scan. Histology following right hemi-
hepatectomy and resection of a further lesion in segment V which 
had been dectected intraoperatively confirmed the diagnosis of a 
large hepatocellular adenoma without any sign of malignancy. 
The pathologist described fatty degeneration of the liver cells and 
only partially regressive changes with slight cicatrisation in the 
adenoma but normal liver tissue without fatty degeneration in the 
physiological liver tissue at the borders of the tumor. Notably, the 
patient’s AFP was slightly elevated at that time. Two years later, in 
March 2000, the patient experienced a new episode of pain under 
the right rib bow. Multiple heterogeneous lesions were detected in 
the patient’s liver upon CT scan. They were highly suspicious of 
malignancy. Exploratory biopsy of these lesions resulted in the 
diagnosis of a HCC. The consulting surgeons assessed them as 
unresectable and the liver as nontransplantable. No risk factors 
for the development of liver cirrhosis or HCC were present in the 
patient’s medical history. A CT scan 5 months later, a period dur-
ing which the patient received 20 mg tamoxifen twice daily, re-
vealed progressive disease. The laboratory workup showed a nor-
mal AFP. The patient was subsequently referred to our outpatient 
clinic. First line chemotherapy consisted of intra-arterial region-
al folinic acid (300 mg, given over 1 h on days 1–5), 5-fluorouracil 
(600 mg/m2, equal to 1,000 mg absolute dose, given over
2 h on days 1–5) and oxaliplatin (110 mg total dose, divided into 
two intra-arterial 4-hour infusions on days 2 and 4, respectively, 
of each treatment cycle), with repetition every 3 weeks. Ultra-
sound controls proved the treatment effective with partial remis-
sion. Unfortunately, this effective regional treatment had to be 
discontinued following occlusion of the hepatic artery after four 
cycles. Second-line chemotherapy consisted of intravenous oxali-
platin (85 mg/m2, equal to 140 mg, given over 2 h) on day 1, fo-
linic acid (500 mg/m2, equal to 1,000 mg, given over 2 h) and high 
dose 5-fluorouracil (2,000 mg/m2, equal to 3,000 mg, given over 
24 h) on day 1 and day 8. This therapy was repeated every 2 weeks. 
Two CT scans during this second line treatment revealed ‘no 
change’. A slightly elevated AFP fell back to normal values. Ox-
aliplatin had to be discontinued in November 2001 following oc-
currence of severe bone pain. Folinic acid and 5-fluorouracil 
weekly were continued until a CT scan discovered progressive 
disease in March 2002. Third-line therapy was initiated: the pa-
tient was treated with liposomal adriamycin (Caelyx, 40 mg/m2, 
equal to 70 mg). This had to be halted after four cycles due to pro-
gressive disease as observed through computed tomography. Af-
ter written informed and institutional consent were obtained, the 
patient was treated as a compassionate use case with liposomally 
encapsulated paclitaxel (EndoTAG  -1). Treatment started in Au-
gust 2002. The first dose consisted of 8 mg total lipid per kg body-
weight and 0.29 mg/kg paclitaxel. The cytostatic content was step-
wise enlarged up to 1.14 mg/kg paclitaxel, the total lipid content 
rose to 32 mg/kg. In 39 doses of monotherapy, the infusion was 
started slowly and accelerated every 10 min. Each application was 
preceded by intravenous administration of 20 mg dexamethasone 
and histamine-blocking agents (H1 and H2 antagonists). The first 
application was carried out in an intensive care unit to ensure 
maximal safety measurements. With only few exceptions, Endo-
TAG-1 was repeated weekly.
 Results
 Safety
 During the first application no adverse effect occurred. 
Yet during the following days, the patient experienced 
fever for more than 1 day. His clinical status worsened 
slightly. After these symptoms had ceased, the adminis-
tration of EndoTAG  -1 was continued on the same dose 
level as during the first application and was as well toler-
ated as during the following 38 doses monotherapy. A 
dose escalation was performed as described above.







 Surprisingly and most encouragingly, this drug ar-
rested tumor growth as seen in computed tomography for 
9 months until a massive progression was observed. The 
progression was evidenced through the worsening of the 
patient’s clinical status and through CT scanning. Con-
comitantly, the AFP rose to values above 2,300 ng/ml. 
The addition of carboplatin to the therapy had to be in-
terrupted due to an acute adverse reaction and due to in-
creased hematotoxicity in November 2003. The patient 
then was subdued to a combination of EndoTAG  -1 and 
DTIC. After 3 months, the patient’s tumor was progres-
sive again in February 2004. One week later, the patient 
died. The time course is depicted in  figure 1 .
 Of note, none of the drugs used is approved for use 
against HCC. There is no evidence for an optimal treat-
ment against intermediate or advanced (BLCL stages B, 
C) HCC. Treatment in the case presented followed expert 
opinion.
 Conclusion
 Intermediate or advanced primary HCC is a disease 
without curative treatment options. Current therapeutic 
concepts consisting of chemotherapy, immunotherapy, 
local interventions or combinations of those fail to achieve 
convincing results. Novel interventions at BCLC stages B 
or C include kinase inhibitors like sorafenib and antian-
giogenic strategies. Using this option, a median time to 
progression of 5.5 months and an overall survival of 10.7 
months was achieved in a recent phase III study  [22] . We 
successfully treated a patient with intermediate (BCLC 
stage B) and progressive HCC with paclitaxel encapsu-
lated in cationic liposomes and achieved a time to pro-
gression of 9 months, exceeding the survival time achieved 
in the SHARP study of sorafenib monotherapy against 
HCC. It is believed that the specific formulation of this 
drug leads to specific adherence to the tumor’s vascula-
ture through physicochemical interactions, delivering 
the drug specifically to the tumor, furthermore starving 
the tumor through antiangiogenic actions. Paclitaxel it-
self has been studied without success against HCC  [49] . 
Yet, in this situation the specific formulation of this drug 
and the drug itself showed efficacy.
 Both options, the inhibition of many kinases in the 
tumor and the antiangiogenetic approach, we report on 
warrant studies in combinations with further cytostatic 
drugs and with each other. Notably, sorafenib is also re-
ported to act against the formation of neovasculature. 
HCC are tumors showing a high degree of (neo)vascula-
ture. Transcatheter arterial chemoembolization (TACE) 
is reported to further enhance this vascularization  [56] . 
If combined with antiangiogenetic approaches, this might 
lead to an even higher degree of tumor starvation.
 Albeit that HCC arising in the noncirrhotic liver, e.g. 
from an adenoma after a metabolic disease as in the case 
presented here, has a better survival compared to HCC 
arising in a cirrhotic liver  [9, 10] , the time to progression 
was measured starting at a very advanced stage of the 
disease where previous therapies failed to achieve a re-
sponse. In general, low remission rates and usually rapid 
disease progression are observed with all drugs tested 
against intermediate and advanced HCC. Thus, a time to 
progression of 9 months even as fourth-line therapy is 
highly remarkable. This warrants phase II studies of
EndoTAG  -1 in HCC as well as in other solid tumors. 
The drug is currently tested in phase II trials against var-
ious types of solid tumors. Medigene, the manufacturer 
of EndoTAG  -1, recently announced the interim results 
of EndoTAG  -1 against inoperable, locally advanced or 
metastasized pancreatic cancer. In this study, gemcitabi-
ne monotherapy was randomized against different doses 
of EndoTAG  -1 in combination with gemcitabine. Me-
dian survival in the group receiving the highest dose of 
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 Fig. 1. Tumor marker (alpha-feto protein, AFP, logarithmic value, 
indicated by  U ) and tumor size (diameter of one lesion in centi-
meters, indicated by  d ) plotted against time. Chemotherapy giv-
en during the respective time is: A: intra-arterial folinic acid + 
5-FU + oxaliplatin; B: intravenous folinic acid + HD 5-FU + ox-
aliplatin; C: caelyx; D: EndoTAG  -1; E: EndoTAG  -1 + carbopla-
tin, later EndoTAG  -1 + DTIC. 
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group by 30%. Survival was even higher in patients who 
received EndoTAG  -1 over a longer period and repeat-
edly. Results from a phase II study against hormone re-
fractory breast cancer will be reported in 2009. In sum-
mary, the approach we present here should be tested ear-
ly in the course of the disease in controlled studies against 
intermediate and advanced HCC.
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